Management of high-risk localized prostate cancer.
Management of high-risk localized prostate cancer.
复制标题
DOI：
10.1155/2012/641689
复制
发表时间：
2012
影响因子：
1.4
通讯作者：
Sanfilippo N
中科院分区：
文献类型：
--
作者：
Marciscano AE;Hardee ME;Sanfilippo N
传统上，由于治疗失败和前列腺癌特异性死亡率（PCSM）的可能性很大，高危局限性前列腺癌患者一直是一个极具挑战性的群体。多项大型前瞻性随机试验的结果表明，具有高危特征的男性在初次诊断时接受多模式治疗可以提高总体生存率。局部治疗的进展，例如剂量递增放疗联合雄激素抑制和前列腺切除术后辅助放疗，也证明了对这部分患者的益处。然而，在主要治疗方案中添加化疗来增强治疗可能有助于实现最佳的疾病控制。
Traditionally, patients with high-risk localized prostate cancer have been an extremely challenging group to manage due to a significant likelihood of treatment failure and prostate cancer-specific mortality (PCSM). The results of multiple large, prospective, randomized trials have demonstrated that men with high-risk features who are treated in a multimodal fashion at the time of initial diagnosis have improved overall survival. Advances in local treatments such as dose-escalated radiotherapy in conjunction with androgen suppression and postprostatectomy adjuvant radiotherapy have also demonstrated benefits to this subset of patients. However, therapeutic enhancement with the addition of chemotherapy to the primary treatment regimen may help achieve optimal disease control.